Cue Biopharma Elevates CBO to Combined Financial and Business Role
Event summary
- Lucinda Warren, currently Cue Biopharma’s Chief Business Officer (CBO), has been appointed Chief Financial and Business Officer (CFBO), effective February 9, 2026.
- Warren has held the CBO role since September 2024.
- Prior to Cue Biopharma, Warren held VP Business Development roles at Johnson & Johnson (2014-2024).
- Warren brings over 30 years of experience in the pharmaceutical and biotechnology sectors.
- The move is reportedly intended to support the advancement of CUE-401, Cue Biopharma’s lead autoimmune asset, toward clinical trials.
The big picture
The appointment of a combined CFBO signals a strategic shift towards integrating financial and business development functions, particularly crucial for clinical-stage biopharma companies navigating capital constraints and regulatory pathways. Warren’s experience at Johnson & Johnson, a company with significant resources, suggests Cue Biopharma is seeking to professionalize its operations and accelerate growth. The move also highlights the increasing demand for executives with both financial and operational expertise in the biotech sector.
What we're watching
- Financial Stability
- Given the company’s recent acknowledgement of a ‘going concern’ determination, Warren’s expanded role will be scrutinized for its impact on financial planning and resource allocation.
- Clinical Progression
- The stated focus on advancing CUE-401 towards the clinic suggests a heightened emphasis on clinical trial execution and potential regulatory hurdles.
- Business Development
- Warren’s extensive business development background suggests potential for increased M&A activity or strategic partnerships to bolster Cue Biopharma’s pipeline.